Volcano has announced the global launch of the PrimeWire Prestige Plus pressure guidewire with AcuSense technology, which allows for more precise measurements when distal pressure is monitored for longer periods of time.
Results from the DISCOVER CE mark trial have shown that the Direct Flow Medical Transcatheter Aortic Valve System met its primary mortality endpoint. The study also demonstrated that greater than 95% of patients had mild or less aortic regurgitation, and no patients experienced vascular complications. Data were presented by co-principal investigator Joachim Schofer, Medical Care Center, Hamburg, Germany, at the TCT congress.
Five-year results from the LEADERS trial have shown improved long-term clinical outcomes for BioMatrix Flex Biolimus A9-eluting stent system (Biosensors) compared to Cypher Select sirolimus-eluting stent system (Johnson & Johnson). BioMatrix Flex significantly reduced the risk of clinical events compared with Cypher Select, which was associated with a reduced risk of very late stent thrombosis (VLST).
CardioKinetix has received CE mark approval for the full size matrix of its Parachute Ventricular Partitioning Device for percutaneous ventricular restoration (PVR) therapy.
Micro Interventional Devices has announced that the first patient has been treated using its self-sealing, cardiac access and closure technology, Permaseal. The patient is the first to be enrolled in the company’s European STASIS clinical trial.
For two decades, doctors have used a dime-sized plug made by St. Jude Medical Inc. to close holes found in the hearts of stroke victims in a surgery that’s based largely on a medical theory.
SAN DIEGO, Oct. 23, 2012 /PRNewswire/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced the global launch of the PrimeWire Prestige® PLUS pressure guide wire with AcuSense technology, which allows for more precise measurements when distal pressure is monitored for longer periods of time. The new offering is the fourth new pressure guide wire from Volcano in four years and will serve as the platform for Volcano s expanding clinical programs. The PrimeWire Prestige PLUS product will be used in six newly announced Volcano-sponsored clinical studies to explore new indications in stable and unstable CAD, peripheral arterial disease and neurology.
At TCT, Paul S Teirstein, Scripps Clinic in La Jolla, California, presented clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the Promus Element Everolimus-Eluting Platinum Chromium (PtCr) Stent System (Boston Scientific) in patients with long coronary lesions.
The US Food and Drug Administration (FDA) has approved the use of the new Gore septal occluder for inclusion in the Gore REDUCE clinical study. Gore is introducing the technology in the REDUCE study for prevention of recurrent stroke in patent foramen ovale (PFO) patients.
The ADVANCE study findings were presented this week at Transcatheter Cardiovascular Therapeutics (TCT) Meeting 2012 (Miami, USA, 22–27 October). Initial one year results of the study revealed that patients experienced high survival rates, with one year survival at 82.1% and one year cardiovascular survival at 88.2% Health-related quality of life (HRQoL) measured for patients in the study had improved significantly at one and six months, compared with their status prior to receiving the Medtronic CoreValve System. The study represents the largest, most rigorously collected evaluation of HRQoL findings published on transcatheter aortic valve implantation (TAVI). The CoreValve System is currently limited to investigational use in the United States.
For the treatment of long lesions and small vessels – two challenging characteristics of coronary artery disease commonly found in patients with diabetes – the Resolute zotarolimus drug-eluting stent from Medtronic delivered successful clinical results, according to new data presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
On 22 October 2012, Svelte Medical Systems announced it received conditional approval from the FDA to begin a pivotal study for the Svelte coronary stent Integrated Delivery System (IDS). Approved by the FDA under an investigational device exemption (IDE), the study will evaluate the safety and effectiveness of the Svelte IDS in approximately 370 patients at up to 30 investigative sites in the USA.
St Jude Medical has announced that an analysis of the benefits to using a fractional flow reserve (FFR)-guided intervention strategy found that the technology can improve patient outcomes while saving significant amounts of money. The analysis, which was funded by an educational research grant from St Jude Medical, found that within each of the country’s respective health care systems, the FFR-guided approach is cost-saving, meaning that use of FFR improves health outcomes for patients with multivessel coronary artery disease at lower costs when compared to using angiography alone.
Cappella has announced the multicentre long term follow-up results for its Sideguard coronary side branch stent. Long term follow-up data on the stent was obtained from 399 patients from the United Kingdom, Germany, and Italy. The MACE rate was: 3.7% (30 day follow-up), 7.1% (six months follow-up) and 10.2% (one year follow-up) comparing favourably with existing standard practice.
On 19 October, the US Food and Drug Administration (FDA) expanded the approved transcatheter aortic valve implantation (TAVI) indication for the Sapien Transcatheter Heart Valve (Edwards Lifesciences) to include patients with aortic valve stenosis who are eligible for surgery, but who are at high risk for serious surgical complications or death.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos